Current Infectious Disease Reports

, Volume 10, Issue 6, pp 505–511 | Cite as

Determinants of HIV shedding in the lower genital tract of women



Heterosexual spread of HIV remains the major risk factor for transmission worldwide. Genital secretions from the infected partner contain both cell-free and cell-associated virus. Although the exact mechanism of heterosexual transmission is unknown, genital virus plays an important role. Decreasing the genital shedding of HIV is an important step in slowing the spread of the disease. Recent studies have shown that antiretroviral penetration into the genital tract varies by class and that antiretroviral therapy significantly decreases HIV levels. Compartmentalization between the blood and genital tract is based on viral load levels, resistant variants, viral diversity, and coreceptor usage. HSV-2, lack of lactobacilli, and plasma cell endometritis increased HIV genital shedding. HSV-2 suppressive therapy significantly reduces plasma and genital tract viral load. Data are conflicting on the effect of hormonal contraception on HIV genital shedding. Further studies are needed to translate these findings into decreased spread on a population level.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    World Health Organization: The 10 leading causes of death by broad income group (2005 projections). Available at Accessed May 2008.
  2. 2.
    Department of Health and Human Services Panel on Antiretroviral Guidelines for Adult and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at Accessed June 9, 2008.
  3. 3.
    Vettore MV, Schechter M, Melo MF, et al.: Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. J Infect 2006, 52:290–293.PubMedCrossRefGoogle Scholar
  4. 4.
    Cu-Uvin S, Snyder B, Harwell JI, et al.: Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006, 42:584–587.PubMedCrossRefGoogle Scholar
  5. 5.
    Lalani T, Hicks C: Does antiretroviral therapy prevent HIV transmission to sexual partners? Curr HIV/AIDS Rep 2007, 4:80–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921–929.PubMedCrossRefGoogle Scholar
  7. 7.
    Cohen MS, Gay C, Kashuba ADM, et al.: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591–601.PubMedGoogle Scholar
  8. 8.
    Chaudry NI, Eron JJ, Naderer OJ, et al.: Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin Infect Dis 2002, 35:760–762.PubMedCrossRefGoogle Scholar
  9. 9.
    Ghosn J, Chaix M-L, Peytavin G, et al.: Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004, 18:1958–1961.PubMedCrossRefGoogle Scholar
  10. 10.
    Min SS, Corbett AH, Rezk N, et al.: Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004, 37:1577–1580.PubMedCrossRefGoogle Scholar
  11. 11.
    Taylor S, van Heeswijk RP, Hoetelmans RM, et al.: Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 2000, 14:1979–1984.PubMedCrossRefGoogle Scholar
  12. 12.
    van Praag RM, van Heeswijk RP, Jurriaans S, et al.: Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001, 33:e91–e92.PubMedCrossRefGoogle Scholar
  13. 13.
    Graham SM, Holte SE, Peshu NM, et al.: Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007, 21:501–507.PubMedCrossRefGoogle Scholar
  14. 14.
    Neely MN, Benning L, Xu J, et al.: Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 44:38–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Taylor S, Pereira AS: Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect 2001, 77:4–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Dumond JB, Yeh RF, Patterson KB, et al.: Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS 2007, 21:1899–1907.PubMedCrossRefGoogle Scholar
  17. 17.
    Kwara A, DeLong AK, Rezk N, et al.: Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008, 46:719–725.PubMedCrossRefGoogle Scholar
  18. 18.
    Andreoletti L, Skrabal K, Perrin V, et al.: Genetic and phenotypic features of blood and genital viral populations of clinically asymptomatic and antiretroviral-treatment-naive clade A human immunodeficiency virus type 1-infected women. J Clin Microbiol 2007, 45:1838–1842.PubMedCrossRefGoogle Scholar
  19. 19.
    Chomont N, Hocini H, Grésenguet G, et al.: Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS 2007, 21:153–162.PubMedCrossRefGoogle Scholar
  20. 20.
    Kemal KS, Burger H, Mayers D, et al.: HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007, 195:535–545.PubMedCrossRefGoogle Scholar
  21. 21.
    Zárate S, Pond SLK, Shapshak P, Frost SDW: Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol 2007, 81:6643–6651.PubMedCrossRefGoogle Scholar
  22. 22.
    Yeaman GR, White HD, Howell A, et al.: The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses 1998, 14(Suppl 1):S57–S62.PubMedGoogle Scholar
  23. 23.
    Wira CR, Fahey JV: A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008, in press.Google Scholar
  24. 24.
    Mestecky J: Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites. J Reprod Immunol 2007, 73:86–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Coleman JS, Hitti J, Bukusi EA, et al.: Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 2007, 21:755–759.PubMedCrossRefGoogle Scholar
  26. 26.
    Clark RA, Theall KP, Amedee AM, Kissinger PJ: Frequent douching and clinical outcomes among HIV-infected women. Sex Transm Dis 2007, 34:985–990.PubMedGoogle Scholar
  27. 27.
    Royce RA, Sena A, Cates W, Cohen MS: Sexual transmission of HIV. N Engl J Med 1997, 336:1072–1078.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaul R, Pettengell C, Sheth PM, et al.: The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2008, 77:32–40.PubMedCrossRefGoogle Scholar
  29. 29.
    Baeten JM, McClelland RS, Corey L, et al.: Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004, 189:1466–1471.PubMedCrossRefGoogle Scholar
  30. 30.
    McClelland RS, Wang CC, Overbaugh J, et al.: Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002, 16:2425–2430.PubMedCrossRefGoogle Scholar
  31. 31.
    Cohen MS, Hoffman IF, Royce RA, et al.: Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997, 349:1868–1873.PubMedCrossRefGoogle Scholar
  32. 32.
    Price MA, Zimba D, Hoffman IF, et al.: Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003, 30:516–522.PubMedCrossRefGoogle Scholar
  33. 33.
    LeGoff J, Weiss HA, Gresenguet G, et al.: Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007, 21:1569–1578.PubMedCrossRefGoogle Scholar
  34. 34.
    Rebbapragada A, Wachihi C, Pettengell C, et al.: Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007, 21:589–598.PubMedCrossRefGoogle Scholar
  35. 35.
    Nagot N, Ouedraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790–799.PubMedCrossRefGoogle Scholar
  36. 36.
    Baeten JM, Strick L, Lucchetti A, et al.: Herpes simplex virus suppressive treatment decreases plasma and genital HIV-1 viral loads in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled crossover trial. Presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.Google Scholar
  37. 37.
    Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560–1571.PubMedCrossRefGoogle Scholar
  38. 38.
    Celum C, Wald A, Hughes J, et al.: HSV-2 suppressive therapy for prevention of HIV acquisition: results of HPTN 039. Presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.Google Scholar
  39. 39.
    Fox-Canale AM, Hope TJ, Martinson J, et al.: Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology 2007, 369:55–68.PubMedCrossRefGoogle Scholar
  40. 40.
    Perinatal HIV Guidelines Working Group: Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at Accessed June 9, 2008.
  41. 41.
    Fawzi W, Msamanga G, Antelman G, et al.: Effect of prenatal vitamin supplementation on lower-genital levels of HIV type 1 and interleukin type 1 beta at 36 weeks of gestation. Clin Infect Dis 2004, 38:716–722.PubMedCrossRefGoogle Scholar
  42. 42.
    Fawzi WW, Msamanga G, Hunter D, et al.: Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J Acquir Immune Defic Syndr 2000, 23:246–254.PubMedGoogle Scholar
  43. 43.
    McClelland RS, Baeten JM, Overbaugh J, et al.: Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial. J Acquir Immune Defic Syndr 2004, 37:1657–1663.PubMedCrossRefGoogle Scholar
  44. 44.
    Baeten JM, Mostad SB, Hughes MP, et al.: Selenium deficiency is associated with shedding of HIV-1-infected cells in the female genital tract. J Acquir Immune Defic Syndr 2001, 26:360–364.PubMedGoogle Scholar
  45. 45.
    Kupka R, Garland M, Msamanga G, et al.: Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005, 39:203–210.PubMedGoogle Scholar
  46. 46.
    Kupka R, Msamanga GI, Xu C, et al.: Relationship between plasma selenium concentrations and lower genital tract levels of HIV-1 RNA and interleukin type 1beta. Eur J Clin Nutr 2007, 61:542–547.PubMedGoogle Scholar
  47. 47.
    Stringer EM, Kaseba C, Levy J, et al.: A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007, 197(2):144.e1–144.e8.CrossRefGoogle Scholar
  48. 48.
    Clark RA, Theall KP, Amedee AM, et al.: Lack of association between genital tract HIV-1 RNA shedding and hormonal contraceptive use in a cohort of Louisiana women. Sex Transm Dis 2007, 34:870–872.PubMedCrossRefGoogle Scholar
  49. 49.
    Losikoff P, Fichorova R, Snyder B, et al.: Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. Infect Dis Obstet Gynecol 2007, 15:1–6.Google Scholar
  50. 50.
    Coombs RW, Wright DJ, Reichelderfer PS, et al.: Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis 2001, 184:1187–1191.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Division of Maternal Fetal MedicineWomen & Infant’s HospitalProvidenceUSA

Personalised recommendations